160 related articles for article (PubMed ID: 17722043)
1. Anti-platelet and anti-thrombotic approaches in patients undergoing percutaneous coronary intervention.
Garg R; Uretsky BF; Lev EI
Catheter Cardiovasc Interv; 2007 Sep; 70(3):388-406. PubMed ID: 17722043
[TBL] [Abstract][Full Text] [Related]
2. Optimal antithrombotic treatment for percutaneous coronary intervention.
Kadakia RA; Ferguson JJ
Minerva Cardioangiol; 2005 Feb; 53(1):15-42. PubMed ID: 15788977
[TBL] [Abstract][Full Text] [Related]
3. [Optimal platelet inhibition after coronary stent implantation. Current status].
Silber S; Hoffmeister HM; Bode C
Herz; 2008 Jun; 33(4):244-53. PubMed ID: 18581073
[TBL] [Abstract][Full Text] [Related]
4. The implications of renal impairment among patients undergoing percutaneous coronary intervention.
Sica D
J Invasive Cardiol; 2002 Apr; 14 Suppl B():30B-37B. PubMed ID: 11967388
[TBL] [Abstract][Full Text] [Related]
5. Emergency percutaneous coronary intervention (PCI) for the care of patients with ST-elevation myocardial infarction (STEMI).
Morrison DA; Berman M; El-Amin O; McLaughlin RT; Bates ER
Minerva Cardioangiol; 2007 Oct; 55(5):593-623. PubMed ID: 17912165
[TBL] [Abstract][Full Text] [Related]
6. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX
Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological and mechanical revascularization strategies in STEMI: integration of the two approaches.
Pollack C
J Invasive Cardiol; 2008 May; 20(5):231-8. PubMed ID: 18460708
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
Ferguson JJ; Wilson JM; Diez J
Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic approach in patients with stable angina.
Lettino M; Falcone C; Tavazzi L
Ital Heart J; 2005 Jan; 6(1):1-8. PubMed ID: 15773267
[TBL] [Abstract][Full Text] [Related]
10. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
11. Thrombelastography: current clinical applications and its potential role in interventional cardiology.
Hobson AR; Agarwala RA; Swallow RA; Dawkins KD; Curzen NP
Platelets; 2006 Dec; 17(8):509-18. PubMed ID: 17127479
[TBL] [Abstract][Full Text] [Related]
12. Stent thrombosis after percutaneous coronary intervention for bifurcation lesions.
Tan HC
J Interv Cardiol; 2009 Apr; 22(2):114-6. PubMed ID: 19379468
[TBL] [Abstract][Full Text] [Related]
13. Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
Spinler SA
Am J Manag Care; 2009 Mar; 15(2 Suppl):S42-7. PubMed ID: 19355808
[TBL] [Abstract][Full Text] [Related]
14. Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
Ivandic BT; Kurz K; Keck F; Staritz P; Lehrke S; Katus HA; Giannitsis E
Thromb Haemost; 2008 Oct; 100(4):648-54. PubMed ID: 18841288
[TBL] [Abstract][Full Text] [Related]
15. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
Cuisset T; Frere C; Quilici J; Gaborit B; Castelli C; Poyet R; Bali L; Morange PE; Alessi MC; Bonnet JL
Am J Cardiol; 2009 Oct; 104(8):1078-82. PubMed ID: 19801028
[TBL] [Abstract][Full Text] [Related]
16. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM;
Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846
[TBL] [Abstract][Full Text] [Related]
17. Revascularization for unprotected left main disease: evolution of the evidence basis to redefine treatment standards.
Kandzari DE; Colombo A; Park SJ; Tommaso CL; Ellis SG; Guzman LA; Teirstein PS; Tamburino C; Ormiston J; Stone GW; Dangas GD; Popma JJ; Bass TA;
J Am Coll Cardiol; 2009 Oct; 54(17):1576-88. PubMed ID: 19833256
[TBL] [Abstract][Full Text] [Related]
18. Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding.
May AE; Geisler T; Gawaz M
Thromb Haemost; 2008 Mar; 99(3):487-93. PubMed ID: 18327396
[TBL] [Abstract][Full Text] [Related]
19. Antiplatelet therapy for improving post-PCI outcomes: interpreting current treatment guidelines for optimal management of the post-ACS patient.
Cross J
Am J Manag Care; 2009 Mar; 15(2 Suppl):S48-53. PubMed ID: 19355809
[TBL] [Abstract][Full Text] [Related]
20. Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study.
Burzotta F; Parma A; Pristipino C; Manzoli A; Belloni F; Sardella G; Rigattieri S; Danesi A; Mazzarotto P; Summaria F; Romagnoli E; Prati F; Trani C; Crea F
Eur Heart J; 2008 Dec; 29(24):3011-21. PubMed ID: 18987096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
